GlassScriptPhysician profile
Catherine Hays
NPI 1720435019
$7,444.87
in general payments reported to CMS, 2019-2025
34 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $1,219 · 2021: $3,647 · 2022: $1,028 · 2023: $52.87 · 2024: $220 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,271.69 | 2021 | |
| Novo Nordisk INC | $977.30 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $775.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $703.35 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $504.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $244.84 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $219.80 | 2019-2022 | |
| Pfizer INC. | $197.05 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.16 | 2020-2022 | |
| Amgen INC. | $182.57 | 2020-2025 | Evenity |
| Esperion Therapeutics, INC. | $181.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $175.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $169.69 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.57 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $150.49 | 2020-2021 | |
| Mylan Specialty L.P. | $138.99 | 2019-2022 | |
| Dexcom, INC. | $116.44 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $89.48 | 2019-2021 | |
| Eisai INC. | $71.71 | 2020-2021 | |
| Astellas Pharma US INC | $66.38 | 2020-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $59.78 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $55.09 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $50.79 | 2019-2020 | |
| Allergan, INC. | $48.41 | 2019-2020 | |
| Exact Sciences Corporation | $38.70 | 2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $33.27 | 2020-2025 | Tirosint, Flector, Licart |
| Bausch Health US, LLC | $24.68 | 2021 | |
| Boston Scientific Corporation | $21.71 | 2025 | General - Therapies |
| Teva Pharmaceuticals USA, INC. | $16.01 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.64 | 2021 | |
| Endo Pharmaceuticals INC. | $13.46 | 2022 | |
| Genentech USA, INC. | $12.74 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.